XXII.NASDAQ22nd Century Group, INC
10-Q: 22nd Century Group Reports Q3 2024 Results: Revenue Declines Amidst Cost-Cutting Efforts
Sentiment:
Quarterly Report
22nd Century Group's Q3 2024 results show a decrease in revenue and a net loss, but also a significant reduction in operating expenses due to cost-cutting measures.
Capital raiseThe company is pursuing financing strategies which include raising additional funds through the issuance of securities.The company has raised capital through various offerings, including registered direct offerings and private placements.The company has issued warrants to purchase common stock as part of its financing activities.
Worse than expectedThe company's revenue decreased by 24.5% in Q3 2024 compared to Q3 2023.The company experienced a gross loss in Q3 2024, compared to a gross profit in Q3 2023.The company has a substantial doubt about its ability to continue as a going concern.
Summary
- 22nd Century Group reported a net revenue of $5.9 million for the third quarter of 2024, a 24.5% decrease compared to $7.9 million in the same period last year.
- The company experienced a gross loss of $0.6 million in Q3 2024, compared to a gross profit of $0.1 million in Q3 2023.
- Operating expenses decreased significantly to $2.8 million in Q3 2024 from $8.3 million in Q3 2023, driven by lower sales, general, and administrative expenses, as well as reduced research and development costs.
- The net loss from continuing operations was $3.6 million in Q3 2024, compared to a net loss of $8.1 million in Q3 2023.
- Basic and diluted loss per common share from continuing operations was $0.27 in Q3 2024, compared to $6.70 in Q3 2023.
- For the nine months ended September 30, 2024, the company's net revenue was $20.4 million, a decrease of 18.1% compared to $24.8 million in the same period last year.
- The company's net loss for the first nine months of 2024 was $10.6 million, compared to a net loss of $111.4 million for the same period in 2023.
- The company had cash and cash equivalents of $5.3 million as of September 30, 2024.
- There is substantial doubt about the company's ability to continue as a going concern through one year following the date that the financial statements are issued.
Sentiment
Score: 3
Explanation: The document indicates significant financial challenges, including declining revenue, gross loss, and substantial doubt about the company's ability to continue as a going concern. While cost-cutting measures are positive, the overall sentiment is negative due to the company's financial instability and reliance on capital raises.
Positives
- Operating expenses decreased significantly due to cost-cutting initiatives.
- The net loss from continuing operations improved compared to the same period last year.
- The company has taken steps to improve liquidity through various financing activities.
- The company has reduced its debt obligations through repayments and conversions.
Negatives
- Net revenue decreased by 24.5% in Q3 2024 compared to Q3 2023.
- The company experienced a gross loss in Q3 2024.
- The company has a substantial doubt about its ability to continue as a going concern.
- VLN cigarette net revenues were negligible in the third quarter 2024 and $70 for the first nine months of 2024.
Risks
- The company faces risks related to the lack of available capital.
- There is a risk of delisting from Nasdaq.
- The company may face future covenant non-compliance with its Senior Secured Credit Facility.
- There are risks associated with the commercialization strategy and market acceptance of the company's products.
- The company is subject to risks inherent in litigation, including purported class actions.
- There are risks related to the protection of proprietary technology.
- The company has a substantial doubt about its ability to continue as a going concern.
Future Outlook
The company is evaluating strategies for reducing expenses and pursuing financing options, including raising additional funds through the issuance of securities, asset sales, and strategic partnerships. There is substantial doubt about the company's ability to continue as a going concern.
Management Comments
- Management is currently evaluating different strategies for reducing expenses.
- Management is pursuing financing strategies which include raising additional funds through the issuance of securities, asset sales, and through arrangements with strategic partners.
Industry Context
The company operates in the tobacco industry, focusing on reduced nicotine products. The results reflect challenges in the market, including lower sales volume and the need for cost-cutting measures. The company is also navigating regulatory requirements and litigation risks.
Comparison to Industry Standards
- The company's revenue decline is significant compared to some of its competitors in the tobacco industry, which have shown more stable or growing revenues.
- The company's cost-cutting measures are in line with industry trends where companies are seeking to improve profitability.
- The company's net loss is substantial compared to some of its peers, indicating a need for further financial restructuring.
- The company's cash position is weak compared to industry leaders, highlighting the need for additional capital raises.
- The company's reliance on debt financing is higher than some of its competitors, which may pose a risk to its long-term sustainability.
Legal Proceedings
- The company is involved in various legal proceedings, including shareholder derivative cases, insurance litigation, a dispute with KeyGene, a dispute with Maison, and a dispute with Cookies Retail Products, LLC.
- The company has accrued liabilities for litigation and regulatory matters when those matters present loss contingencies that are both probable and estimable.
Stakeholder Impact
- Shareholders are impacted by the company's financial instability and the potential for delisting from Nasdaq.
- Employees are impacted by the company's cost-cutting measures, including headcount reductions.
- Customers may be impacted by the company's product offerings and distribution strategies.
- Creditors are impacted by the company's debt obligations and its ability to repay them.
- Suppliers may be impacted by the company's financial instability and its ability to pay for goods and services.
Next Steps
- The company will continue to evaluate strategies for reducing expenses.
- The company will pursue financing strategies to raise additional funds.
- The company will seek shareholder approval for the Conversion Price reset of the Debentures.
- The company will hold an annual or special meeting on or before May 30, 2025, to have stockholders approve the issuance of the shares of common stock underlying the warrants.
Key Dates
| Date | Description |
|---|---|
| 2021-10-29 | Date of the 12% Secured Promissory Note with a principal amount of $1,000 payable to Omnia. |
| 2022-01-14 | Date of the 12% Secured Promissory Note with a principal amount of $1,500 payable to Omnia. |
| 2022-03-03 | Date of the Senior Secured Debentures. |
| 2022-11-01 | Date of the fire at the company's Grass Valley manufacturing facility. |
| 2023-03-03 | Date of the Subordinated Promissory Note with a principal amount of $2,865 in favor of Omnia Ventures, LP. |
| 2023-06-22 | Date of the issuance of JGB Warrants. |
| 2023-07-05 | Date of the 1-for-15 reverse stock split. |
| 2023-07-19 | Date the company filed a complaint against Dorchester Insurance Company, Ltd. |
| 2023-10-16 | Date the company entered into a Waiver and Amendment Agreement with the holders and the agent. |
| 2023-11-28 | Date the company commenced a warrant inducement offering with the holders of the company's outstanding warrants. |
| 2023-12-05 | Date the parties entered into a Memorandum of Settlement to fully resolve all claims pending the Courts approval of a motion for preliminary approval of settlement. |
| 2023-12-22 | Date the company, the holders and the agent entered into an Amendment Agreement. |
| 2024-01-08 | Date the company formally terminated both Framework Collaborative Research Agreements, as amended, related to hemp/cannabis and hops. |
| 2024-01-23 | Date the company received a Notice of Intent to Arbitrate from Maison Placements Canada Inc. |
| 2024-02-06 | Date Melvyn Klein filed a shareholder derivative claim against the company. |
| 2024-02-15 | Date of shareholder approval for the 2023 Inducement Warrants. |
| 2024-03-28 | Date of the 1-for-16 reverse stock split. |
| 2024-04-02 | Date the company effected a 1-for-16 reverse stock split of its common stock. |
| 2024-04-08 | Date the company and certain investors entered into a securities purchase agreement relating to the issuance and sale of shares of common stock. |
| 2024-04-11 | Date the company received a Request for Arbitration from Keygene N.V. |
| 2024-04-29 | Date the company entered into a General Release and Settlement Agreement with Omnia Capital LP. |
| 2024-05-10 | Date the company, the holders and the agent entered into that certain May 2024 Exchange Agreement and May 2024 Letter Agreement. |
| 2024-06-24 | Effective date GVB Biopharma made a scheduled principal and interest payment against the company's outstanding indebtedness to JGB. |
| 2024-06-28 | Date the Voluntary Conversion Option was approved by the company's shareholders. |
| 2024-07-16 | Date the company received a deficiency letter from the Nasdaq Listing Qualifications Department. |
| 2024-07-25 | Date an arbitrator was formally appointed in the Keygene dispute. |
| 2024-08-27 | Date the company, the holders and the agent entered into that certain August 2024 Letter Agreement. |
| 2024-09-27 | Date the company and certain investors entered into a securities purchase agreement relating to the issuance and sale of shares of common stock. |
| 2024-09-29 | Date the company commenced a warrant inducement offering with the holders of outstanding warrants. |
| 2024-09-30 | End of the reporting period for the quarterly report. |
| 2024-10-10 | Date the company entered into that certain Letter Agreement to modify the terms of the Debentures with JGB. |
| 2024-10-11 | Date the company and certain investors entered into a securities purchase agreement relating to the issuance and sale of shares of common stock. |
| 2024-10-23 | Date the company and certain investors entered into a securities purchase agreement relating to the issuance and sale of prefunded warrants to purchase shares of common stock. |
| 2024-10-23 | Date Cookies Retail Products, LLC filed a complaint against the company. |
| 2024-11-04 | Trial date for the insurance litigation. |
| 2024-11-08 | Date of the share count. |
| 2024-11-12 | Date of the report. |
| 2024-12-18 | Hearing date for the Motion for Partial Summary Judgment in the insurance litigation. |
| 2024-12-31 | The company has agreed to seek shareholder approval for the Conversion Price reset pursuant to applicable Nasdaq rules no later than this date. |
| 2025-03-24 | Arbitration date for the Keygene dispute. |
| 2025-05-30 | The company has agreed to hold an annual or special meeting on or before this date, to have stockholders approve the issuance of the shares of common stock underlying the warrants. |
Keywords
tobacco, reduced nicotine, contract manufacturing, financial results, cost reduction, liquidity, warrants, debt, going concern, litigation
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.